Affiliations: [a] Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
| [b] Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA
| [c] Department of Urology, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang, China
Correspondence:
[*]
Corresponding authors: Boxin Xue, Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Tel.: +86 18994392817; E-mail: [email protected] and Gang Wang, Department of Urology, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang, China. Tel.: +86 13989308247; E-mail: [email protected].
Abstract: Purpose:To evaluate safety, efficacy and clinical outcomes after photovaporization of the prostate with the 180W-XPS Greenlight laser in patients with low urinary tracts symptom secondary to benign prostatic hyperplasia (BPH). Materials and Methods:All 102 patients with lower urinary tract symptoms who underwent 180W XPS laser vaporization of the prostate from April 2017 to April 2018 were enrolled. The preoperative parameters, postoperative functional, uroflowmetry outcomes and complications were collected. Results:All patients were successfully treated with 180W XPS laser vaporization. Mean preoperative prostate volume was 81±28.7 ml and mean laser time was 28.2±12.5 minutes. No major complications intraoperatively or postoperatively were observed and no blood transfusions were required. Comparing to preoperative characteristics, International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and post-void residual (PVR) parameters were improved significantly and sustained during the follow-up period. At 3, 6 and 12-month follow-ups, mean urinary peak flow increased from 6.2±2.1 ml per second to 19.8±4.6, 19.4±4.7 and 19.6±4.9 ml per second, respectively. Mean International Prostate Symptom Scores decreased over time, from 28.9±4.5 to 8.2±1.6, 6.2±1.22 and 5.88±1.15 at 3, 6, 12 months, respectively. Conclusions:180W XPS Greenlight laser vaporization is a safe and effective treatment option for patients with lower urinary tract symptoms secondary to BPH.
